Post-transcriptional control of mRNA localization, stability, and translation is a fundamentally important, yet largely underexplored, mechanism of gene regulation that contributes to virtually every aspect of cellular physiology. In many cases, elements within the 3' untranslated region (UTR) of a given mRNA transcript confer responsiveness to microRNAs and/or binding proteins, which may dictate the fate of the transcript. One physiological process in which post-transcriptional regulation of gene expression has been demonstrated to play an important role is the epithelial to mesenchymal transition (EMT). EMT is thought to initiate tumor metastasis by altering the shape, invasiveness, and motility of carcinoma cells within the primary tumor. The breast epithelial cell line MCF10a undergoes EMT in response to treatment with the cytokine TGF-. Using density gradient fractionation and Next Generation Sequencing, we have examined polysomal enrichment and depletion in MCF10a cells in both the epithelial and mesenchymal states. Within our model system, we have identified 54 gene products that are preferentially translated (4-fold or more enrichment over total mRNA) in the mesenchymal state. Among these gene products is SNAI1, a known driver of EMT in several experimental systems. The nature of the mechanism driving this polysomal enrichment, and whether the remainder of the observed gene products contribute to the initiation or maintenance of the mesenchymal state, are both unclear. The proposed research is designed to assess the feasibility of a template for prospective identification of nove translational regulators within our system. Our hypothesis is two-fold: firstly, that these gene products functionally contribute to the initiation or maintenance of the mesenchymal state, and secondly, that their preferential translation is modulated by the interaction of a common factor with the 3' UTRs of these transcripts. To test these hypotheses, we will employ paired functional genomic approaches that are mutually informative but non-interdependent. Via overexpression and RNAi knockdown, we will determine whether the identified gene products are necessary and sufficient for EMT in three distinct models of this process. In parallel, we will employ a novel, scalable, transposon-based reporter platform to define for which of these mRNA transcripts the 3' UTR confers the translational control. Whether a cis-regulatory element common to many of these transcripts underlies this control will also be directly assessed. Finally, we will use biochemical and molecular methods to prospectively identify and characterize putative trans-regulators binding these putative cis-elements, under the rationale that these trans-regulators may integrate post-transcriptional gene regulation in the EMT programs. Novel regulators of EMT identified in our model system, both direct effectors and the trans-factors that regulate them, are potential targets for therapeutic intervention aimed at preventing metastasis of early-stage cancers. Further, successful implementation of our approach will result in a generalized template that can be leveraged in other cell-based models of tumorigenesis.

Public Health Relevance

The epithelial to mesenchymal transition (EMT) is a process thought to underlie metastasis in human cancer. In a cell-based model of this process, we have identified messenger RNA derived from scores of genes that is preferentially used to make protein in the motile, mesenchymal cell type. We propose to determine how these genes individually contribute to EMT and to identify the factor(s) allowing these messenger RNAs to be preferentially used in mesenchymal cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA185769-01A1
Application #
8956695
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Strasburger, Jennifer
Project Start
2015-05-15
Project End
2017-04-30
Budget Start
2015-05-15
Budget End
2016-04-30
Support Year
1
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Physiology
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Reineke, Lucas C; Neilson, Joel R (2018) Differences between acute and chronic stress granules, and how these differences may impact function in human disease. Biochem Pharmacol :
Reineke, Lucas C; Cheema, Shebna A; Dubrulle, Julien et al. (2018) Chronic starvation induces noncanonical pro-death stress granules. J Cell Sci 131:
Yang, Jian; Kongchan, Natee; Primo Planta, Cecilia et al. (2017) The atypical genesis and bioavailability of the plant-based small RNA MIR2911: Bulking up while breaking down. Mol Nutr Food Res 61:
Palmieri, Michela; Pal, Rituraj; Nelvagal, Hemanth R et al. (2017) mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases. Nat Commun 8:14338
Tajhya, Rajeev B; Hu, Xueyou; Tanner, Mark R et al. (2016) Functional KCa1.1 channels are crucial for regulating the proliferation, migration and differentiation of human primary skeletal myoblasts. Cell Death Dis 7:e2426
Chaudhury, Arindam; Neilson, Joel R (2016) Use of the pBUTR Reporter System for Scalable Analysis of 3' UTR-Mediated Gene Regulation. Methods Mol Biol 1358:109-28
Pal, Rituraj; Bajaj, Lakshya; Sharma, Jaiprakash et al. (2016) NADPH oxidase promotes Parkinsonian phenotypes by impairing autophagic flux in an mTORC1-independent fashion in a cellular model of Parkinson's disease. Sci Rep 6:22866
Chaudhury, Arindam; Cheema, Shebna; Fachini, Joseph M et al. (2016) CELF1 is a central node in post-transcriptional regulatory programmes underlying EMT. Nat Commun 7:13362
Domingues, Rita G; Lago-Baldaia, InĂªs; Pereira-Castro, Isabel et al. (2016) CD5 expression is regulated during human T-cell activation by alternative polyadenylation, PTBP1, and miR-204. Eur J Immunol 46:1490-503
Xu, Yang; Chaudhury, Arindam; Zhang, Ming et al. (2016) Glycolysis determines dichotomous regulation of T cell subsets in hypoxia. J Clin Invest 126:2678-88

Showing the most recent 10 out of 12 publications